Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;37(6):1077-1086.
doi: 10.1007/s10557-022-07357-5. Epub 2022 Jun 17.

Non-VKA Oral Anticoagulants in Adult Congenital Heart Disease: a Single-Center Study

Pedro Garcia Brás  1 , Tânia Branco Mano  2 , Tiago Rito  3 , Alexandra Castelo  2 , Vera Ferreira  2 , Ana Agapito  2 , Rui Cruz Ferreira  2 , Fatima Pinto  3 , Lídia de Sousa  2
Affiliations

Non-VKA Oral Anticoagulants in Adult Congenital Heart Disease: a Single-Center Study

Pedro Garcia Brás et al. Cardiovasc Drugs Ther. 2023 Dec.

Abstract

Purpose: Non-VKA oral anticoagulants (NOACs) prescription is increasing in adults with congenital heart disease (ACHD). However, data on efficacy and safety in ACHD is unclear, particularly in severe CHD. The study aimed to review the safety and efficacy of NOACs in ACHD.

Methods: Retrospective evaluation of ACHD patients started on NOACs from 2014 to 2020, with the primary endpoints of bleeding or thromboembolic events (TE). CHA2DS2-VASc and HAS-BLED scores were calculated, mortality was assessed, and risk factors for bleeding were identified.

Results: A total of 93 patients were included, the mean age was 52 ± 15 years, 58% were female, 55.9% had moderate CHD, and 23.7% had severe CHD (3.2% Fontan). Most (66%) had a CHA2DS2-VASc score ≥ 2 and 82% HAS-BLED ≤ 2. In a median follow-up of 41 (IQR 21) months (400.4 patient-years), there were TE in two patients. The annual risk for TE was 0.49%/patient/year. The cardiovascular mortality was 2% and all-cause mortality 5%; there were no fatal TE or bleeding events. Minor (n = 6, 6.5%) and major (n = 3, 3.2%) bleeding events were observed, a median of 12 (IQR 15) months after starting NOAC therapy. The annual risk for bleeding was 2.2%/patient/year. Renal disease (HR 14.6 [95% CI 1.23-73.6], p = 0.033) and the HAS-BLED score were predictors of major (adjusted HR 6.97 [95% CI 1.69-28.78], p = 0.007) and minor (adjusted HR 3.80 [95% CI 1.48-9.78], p = 0.006) bleeding complications.

Conclusion: In this real-life cohort of selected ACHD, the use of NOACs was safe and effective, with a low incidence of bleeding events.

Keywords: Adult congenital heart disease; Antithrombotic therapy; NOACs; Non-VKA oral anticoagulants.

PubMed Disclaimer

References

    1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. - DOI - PubMed
    1. Freisinger E, Gerß J, Makowski L, et al. Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients. Eur Heart J. 2020;41(43):4168–77. - DOI - PubMed
    1. Jensen A, Idorn L, Nørager B, et al. Anticoagulation in adults with congenital heart disease: the who, the when and the how. Heart. 2015;101(6):424–9. - DOI - PubMed
    1. Mekaj Y, Mekaj A, Duci S, Miftari E. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77. - DOI - PubMed - PMC
    1. Yang H, Veldtman G, Bouma B, et al. Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe. Heart. 2019;6(1):e000985.

LinkOut - more resources